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Purpose: To evaluate intracranial control after surgical resection according to the adjuvant treatment received in order to assess 
the optimal radiotherapy (RT) dose and volume.
Materials and Methods: Between 2003 and 2015, a total of 53 patients with brain oligometastases from non-small cell lung 
cancer (NSCLC) underwent metastasectomy. The patients were divided into three groups according to the adjuvant treatment 
received: whole brain radiotherapy (WBRT) ± boost (WBRT ± boost group, n = 26), local RT/Gamma Knife surgery (local RT group, 
n = 14), and the observation group (n = 13). The most commonly used dose schedule was WBRT (25 Gy in 10 fractions, equivalent 
dose in 2 Gy fractions [EQD2] 26.04 Gy) with tumor bed boost (15 Gy in 5 fractions, EQD2 16.25 Gy). 
Results: The WBRT ± boost group showed the lowest 1-year intracranial recurrence rate of 30.4%, followed by the local RT and 
observation groups, at 66.7%, and 76.9%, respectively (p = 0.006). In the WBRT ± boost group, there was no significant increase 
in the 1-year new site recurrence rate of patients receiving a lower dose of WBRT (EQD2) <27 Gy compared to that in patients 
receiving a higher WBRT dose (p = 0.553). The 1-year initial tumor site recurrence rate was lower in patients receiving tumor bed 
dose (EQD2) of ≥42.3 Gy compared to those receiving <42.3 Gy, although the difference was not significant (p = 0.347).
Conclusions: Adding WBRT after resection of brain oligometastases from NSCLC seems to enhance intracranial control. 
Furthermore, combining lower-dose WBRT with a tumor bed boost may be an attractive option.
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Introduction
The incidence of brain metastasis is rising recently due to 
increasing survival from advances in systemic therapy and 
imaging technology such as magnetic resonance imaging. 
Among brain metastases, the most common primary site is 
undoubtedly the lungs, with brain metastases incidence rates 
ranging from 20% to 50% [1,2]. Even after the diagnosis of 
brain metastasis, patients are expected to survive longer than 
before due to improvements in cancer treatment. Therefore, 
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it is imperative to choose the optimal adaptive treatment 
modality with the least neurotoxicity. Furthermore, the 
longer expected survival times make it increasingly important 
to improve intracranial control and reduce neurotoxicity, 
especially in patients with brain oligometastases [3].
Surgical resection is recommended in oligometastases for 
local control and symptom palliation [4]. After metastasectomy, 
the various adjuvant treatment options include whole brain 
radiotherapy (WBRT), local radiotherapy (RT) to the tumor bed, 
or observation with best supportive care. Traditionally, WBRT 
has been commonly performed, with a typical dose of 30 Gy 
in 10 fractions. Even though numerous studies have tried to 
determine the optimal dose and fractionation for WBRT, it 
remains controversial [5-9]. There is no doubt of the effect of 
WBRT on intracranial control, but there has been an increasing 
concern for the adverse effect of WBRT on neurocognitive 
function [10,11]. Since WBRT neurotoxicity is associated 
with the total dose and fractionation, lower adjuvant WBRT 
doses with a boost to the tumor bed and the residual tumor 
have been performed in our institution in order to decrease 
neurotoxicity and to ensure adequate tumor bed control [12-
14]. As the prognosis of brain metastases varies according to 
the primary tumor site, a study regarding the proper treatment 
of brain metastases should be performed in a homogenous 
group of patients with the same primary tumor [3]. The 
development of targeted therapy has improved survival, 
especially in non-small cell lung cancer (NSCLC), which has 
increased the importance of choosing the optimal treatment 
modality for brain metastasis. Thus, this study focused only on 
brain oligometastases from NSCLC.
The purpose of this study was to compare the intracranial 
control rates of WBRT ± boost RT, local RT, and observation 
after the surgical resection of metastatic brain lesions 
from NSCLC. In addition, the efficacy of a lower WBRT dose 
with a boost to the tumor bed and residual tumor was also 
investigated.
Materials and Methods
1. Patients
We retrospectively reviewed the medical records of 130 
patients with 1 to 4 brain metastases of primary NSCLC who 
received metastasectomy between November 2003 and June 
2015 at a single institution. Patients who previously received 
WBRT (n = 22), died after surgery (n = 2), died or moved to 
hospice care during RT (n = 2), or had no follow-up imaging 
after surgery (n = 51) were excluded. The remaining 53 patients 
were divided into three groups according to the adjuvant 
treatment received. The WBRT ± boost group (n = 26) included 
patients who received WBRT alone or WBRT with tumor bed 
boost. The local RT group (n = 14) included patients who 
received local RT or Gamma Knife surgery (GKS) without WBRT. 
Local RT was defined as RT to the tumor bed with a suitable 
margin. The observation group (n = 13) included patients who 
were closely observed without RT. Brain metastases diagnosed 
with primary NSCLC at the time of diagnosis were defined 
as synchronous. Patients defined as having a ‘new’ brain 
metastasis diagnosis were those who were diagnosed with 
brain metastasis for the first time, while ‘recurrent’ included 
patients who had a previous history of brain metastasis. For 
‘recurrent’ brain metastases patients, previous treatment 
modalities were GKS 3 times for one patient and GKS once for 
3 patients.
2. Treatment
All patients complained of symptoms due to brain metastasis 
prior to surgery. Surgery was performed mainly to resect 
the symptom-provoking lesion and other metastatic lesions 
if possible. In terms of the extent of the surgical resection, 
gross total resection (GTR) was defined as the removal of all 
metastatic lesions, while residual was defined as the subtotal 
removal of the main mass or the presence of other brain 
metastatic lesions. GTR was achieved in 100% of patients 
with single lesions and in 3.7% of patients with multiple 
lesions. The median time interval between surgery and the 
start of postoperative RT was 19 days (range, 2 to 108 days). 
All patients but one received RT within 37 days. One patient 
received local RT (GKS) 108 days after surgery due to wound 
revision and removal of epidural hemorrhage. Postoperative 
RT doses and volumes were determined according to the 
physicians’ preferences. The total biological effective dose 
was calculated as equivalent dose in 2 Gy fractions (EQD2: α/
β value of 3 for normal tissue [Gy3] and 10 for tumor [Gy10]). 
The various WBRT and boost dose schedules are shown in 
Supplementary Table S1. The most commonly used dose 
schedule was WBRT as 25 Gy in 10 fractions (EQD2 26.04 Gy) 
with a tumor bed boost of 15 Gy in 5 fractions (EQD2 16.25 
Gy). Only half of those patients who received WBRT 30 Gy 
received a tumor bed boost. WBRT was generally administered 
using 3D-conformal RT, except for 6 patients who received 
intensity-modulated radiotherapy (IMRT) with a simultaneous-
integrated-boost (SIB) to the tumor bed. In the local RT group, 
9 patients received GKS 14–15 Gy prescribed to the 50% 
isodose line, 3 patients received hypofractionated RT (25–40 
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Gy in 10–15 fractions), and 2 patients received conventional 
fractionation RT (45 Gy in 25 fractions).
For postoperative systemic treatment, 11 (20.8%) and 25 
(47.2%) patients received targeted therapy and chemotherapy, 
respectively. The targeted therapy included gefitinib (n = 5), 
erlotinib (n = 5) and afatinib (n = 1). The mutational status 
was checked in 32 patients, which revealed EGFR mutations 
in 13 patients (24.5%) and ALK mutations in 1 (1.9%). For the 
patients who were in a systemic progressive status, the median 
time interval between surgery and the start of systemic 
chemotherapy were: WBRT ± boost group 21 days (range, 
12–62 days), local RT group 20 days (range, 10 to 62 days), and 
observation group 19.5 days (range 12 to 40 days).
3. Outcome evaluations
The median follow-up period was 17.0 months (range, 3.0 
to 118 months). Follow-up was performed regularly, at least 
every 3 months after surgery, by magnetic resonance imaging 
(MRI). Initial site recurrence (ISR) was defined as initial tumor 
bed recurrence or progression. New site recurrence (NSR) was 
defined as intracranial recurrence (IR) beyond the initial tumor 
bed including leptomeningeal and parenchymal seeding. IR 
was defined as all intracranial recurrences including ISR and 
NSR. Overall survival was defined as the time from surgery 
until death or the last date that the patient was known to 
be alive. The IR, ISR, and NSR were defined as the time from 
surgery until the event of recurrence or the date of last follow-
up in our institution.
4. Statistical analysis
The cumulative probability of the IR, ISR, NSR, and overall 
survival rates were calculated by the Kaplan-Meier method 
and compared by log-rank tests. Univariate and multivariate 
analyses were performed using Cox regression. Multivariate 
analysis was performed using a backward elimination 
approach including all variables. All analyses were performed 
using IBM SPSS Statistics for Windows, ver 20.0 (IBM, Armonk, 
NY, USA).
Results
1. Patient and tumor characteristics
The patient and tumor characteristics are shown in Table 1. 
The median age of all patients was 56 years (range, 37 to 85 
years), and most were confirmed as having adenocarcinoma 
(83.0%). About half of the patients had single metastasis, 
with the remaining having multiple metastases. The median 
maximum size of the metastatic lesion was 41 mm (range, 
22 to 65 mm). The patient and tumor characteristics such as 
gender, pathology, systemic status, synchronicity, time of brain 
metastasis diagnosis, number of brain metastasis, maximum 
size, location, surgery, graded prognostic assessment (GPA) 
score, mutation subtype, and systemic treatment after surgery 
did not differ among the three groups. 
2. Intracranial recurrence
The 1-year IR rate of all patients was 40.6%. In the WBRT ± 
boost, local RT, and observation groups, the 1-year IR rates 
were 30.4%, 66.7%, and 76.9%, respectively (p = 0.006) (Fig. 
1A). In univariate analysis, the adverse factors for IR included 
squamous cell carcinoma or other pathology (hazard ratio 
[HR], 3.86; 95% confidence interval [CI], 1.62–9.20; p = 0.002), 
recurrent brain metastasis (HR, 3.81; 95% CI, 1.27–11.44; 
p = 0.017), and multiple brain metastases (HR, 2.21; 95% 
CI, 1.02–4.78; p = 0.044). The favorable factors included 
targeted therapy as a postoperative systemic treatment 
compared to none (HR, 0.18, 95% CI, 0.04–0.79; p = 0.023) 
and WBRT ± boost as a treatment modality when compared 
to observation (HR, 0.25; 95% CI, 0.10–0.62; p = 0.003). In 
multivariate analysis, IR was adversely affected by recurrent 
brain metastasis (HR, 13.35; 95% CI, 2.60–68.65; p = 0.002) 
and beneficially affected by stable (HR, 0.14; 95% CI, 0.02–0.97; 
p = 0.046) or NED (HR, 0.20; 95% CI, 0.05–0.79; p = 0.022) 
systemic status compared to progressive systemic status 
and WBRT ± boost as treatment modality when compared to 
observation (HR, 0.23; 95% CI, 0.09–0.63; p = 0.004) (Table 2). 
Local RT as a treatment modality compared to observation did 
not prove to be a significant factor (HR, 0.47; 95% CI, 0.19–
1.17; p = 0.105).
3. New site recurrence
A total of 29 patients experienced NSR: 22 patients had 
new parenchymal recurrence, 4 had seeding metastasis, and 
3 had both. The 1-year NSR rates were 30.7%, 67.3%, and 
76.9% in the WBRT ± boost, local RT, and observation groups, 
respectively (p = 0.006) (Fig. 1B). The results of multivariate 
analysis were similar to those of IR. NSR was adversely affected 
by recurrent brain metastasis (HR, 12.79; 95% CI, 2.48–65.92; 
p = 0.002) and beneficially affected by stable (HR, 0.12; 95% 
CI, 0.02–0.88; p = 0.037) or NED (HR, 0.19; 95% CI, 0.05–0.76; 
p = 0.019) systemic status compared to progressive status and 
WBRT ± boost as a treatment modality when compared to 
observation (HR, 0.24; 95% CI, 0.09–0.64; p = 0.004) (Table 2). 
In addition, subgroup analysis of the WBRT ± boost group was 
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Table 1. Patient and tumor characteristics
Total
(n = 53)
WBRT ± boost
(n = 26)
Local RT
(n = 14)
No RT
(n = 13)
p-value
Age (yr)
Sex
    Male
    Female
Pathology
    Adenoca
    SCCa
    Other
Systemic status
    Progression
    Stable
    NED
Synchronous
    Synchronous
    Metachronous
Brain metastasis diagnosis
    New
    Recurrent
Number of metastasis
    Single
    Multiple
Maximum size of metastasis (mm)
    <40
    ≥40
Location of metastasis
    Supratentorial
    Infratentorial
    Both
Surgery extent
    Residual
    GTR
GPA
    0.0–1.0
    1.5–2.0
    2.5–3.0
    3.5–4.0
Mutation subtype
    Unknown
    None
    EGFR
    ALK
Systemic Tx after surgery
    None
    Targeted Tx
    CTx without targeted Tx
WBRT dose (Gy) (EQD2)
Tumor bed dose (Gy) (EQD2)
 56 (37–85)
 37 (69.8)
 16 (30.2)
 44 (83)
 4 (7.5)
 5 (9.4)
 39 (73.6)
 3 (5.7)
 11 (20.8)
 34 (64.2)
 19 (35.8)
 49 (92.5)
 4 (7.5)
 26 (49.1)
 27 (50.9)
 41 (22–65)
 21 (39.6)
 32 (60.4)
 32 (60.4)
 8  (15.1)
 13 (24.5)
 26 (49.1)
 27 (50.9)
 8 (15.1)
 14 (26.4)
 20 (37.7)
 11 (20.8)
 21 (39.6)
 18 (3.4)
 13 (24.5)
 1 (1.9)
 17 (32.1)
 11 (20.8)
 25 (47.2)
-
-
 56 (37–85)
 19 (73.1)
 7 (26.9)
 24 (92.3)
 1 (3.8)
 1 (3.8)
 18 (69.2)
 1 (3.8)
 7 (26.9)
 16 (61.5)
 10 (38.5)
 24 (92.3)
 2 (7.7)
 14 (53.8)
 12 (46.2)
 42 (22–56)
 9 (34.6)
 17 (65.4)
 16 (61.5)
 4 (15.4)
 6 (23.1)
 12 (46.2)
 14 (53.8)
 4 (15.4)
 5 (19.2)
 11 (42.3)
 6 (23.1)
 7 (26.9)
 12 (46.2)
 7 (26.9)
 0 (0)
 7 (26.9)
 7 (26.9)
 12 (46.2)
 26.04 (20.8–39.1)
 44.3 (42.3–50.0)
 60 (37–78)
 7 (50)
 7 (50)
 12 (85.7)
 1 (7.1)
 1 (7.1)
 11 (78.6)
 1 (7.1)
 2 (14.3)
 9 (64.3)
 5 (35.7)
 13 (92.9)
 1 (7.1)
 6 (42.9)
 8 (57.1)
 41 (24–65)
 5 (35.7)
 9 (64.3)
 7 (50)
 2 (14.3)
 5 (35.7)
 8 (57.1)
 6 (42.9)
 1 (7.1)
 7 (50)
 4 (28.6)
 2 (14.3)
 8 (57.1)
 3 (21.4)
 3 (21.4)
 0 (0)
 4 (28.6)
 2 (14.3)
 8 (57.1)
-
 88.7 (26.0–100.0)
 56 (37–80)
 11 (84.6)
 2 (15.4)
 8 (61.5)
 2 (15.4)
 3 (23.1)
 10 (76.9)
 1 (7.7)
 2 (15.4)
 9 (69.2)
 4 (30.8)
 12 (92.3)
 1 (7.7)
 6 (46.2)
 7 (53.8)
 39 (27–64)
 7 (53.8)
 6 (46.2)
 9 (69.2)
 2 (15.4)
 2 (15.4)
 6 (46.2)
 7 (53.8)
 3 (23.1)
 2 (15.4)
 5 (38.5)
 3 (23.1)
 6 (46.2)
 3 (23.1)
 3 (23.1)
 1 (7.7)
 6 (46.2)
 2 (15.4)
 5 (38.5)
-
-
0.151*
0.148*
0.839*
0.894
1.000*
0.780
0.482
0.817*
0.780
0.504*
0.280*
0.699*
Values are presented as median (range) or number (%).
Adenoca, adenocarcinoma; SCCa, squamous cell carcinoma; NED, no evidence of disease; GTR, gross total removal; GPA, graded prog-
nostic assessment; Tx, treatment; CTx, chemotherapy; WBRT, whole brain radiotherapy.
* Fisher’s exact test.
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performed in order to investigate the relationship between 
NSR and WBRT dose. Since the most commonly used dose 
schedule was WBRT 25 Gy in 10 fractions (EQD2 26.04 Gy), the 
WBRT ± boost group was divided into WBRT dose (EQD2) <27 
Gy (n = 16) and ≥27 Gy (n = 10) groups. The 1-year NSR rates 
were not significantly different between the patients receiving 
WBRT dose (EQD2) <27 Gy and ≥27 Gy (40.9% and 27.3%, 
respectively; p = 0.553) (Fig. 2).
4. Initial site recurrence
The 1-year ISR rates were 10.3%, 9.1%, and 24.8% in the 
WBRT ± boost, local RT, and observation groups, respectively (p 
= 0.410) (Fig. 1C). Recurrent brain metastasis (HR, 29.22; 95% 
CI, 4.75–179.72; p < 0.001) proved to be the single adverse 
factor for ISR by univariate analysis, but not by multivariate 
analysis. For ISR, subgroup analysis was performed for the 
WBRT ± boost and local RT groups combined in order to 
determine the relationship between ISR and total RT dose 
delivered to the tumor bed. The subgroup was divided into 
tumor bed dose (EQD2) <42.3 Gy and ≥42.3 Gy groups because 
the most commonly used dose schedule was WBRT 25 Gy in 10 
fractions (EQD2 26.04 Gy) with a tumor bed boost of 15 Gy in 
5 fractions (EQD2 16.25 Gy), which summed to a total of EQD2 
42.29 Gy to the tumor bed. The 1-year ISR rate was lower in 
patients receiving tumor bed dose (EQD2) ≥42.29 Gy compared 
to those receiving <42.29 Gy (5.0% vs. 21.2%, p = 0.347), but 
the difference was not significant (Fig. 3).
5. Overall survival
The median overall survival of all patients was 18.7 months. 
The difference in overall survival among the three groups 
was not significant (p = 0.667) (Fig. 4). The 1-year survival 
rates were 79.3%, 78.6%, and 69.2% in the WBRT ± boost, 
local RT, and observation groups, respectively. In multivariate 
analysis, the postoperative treatment modality did not remain 
a significant factor. Factors such as age older than 65 years, 
progressive systemic disease status, metachronous brain 
metastasis, recurrent brain metastasis, metastatic lesion size 
≥40 mm, and lower GPA score were significant adverse factors 
for overall survival (Supplementary Table S2).
Discussion and Conclusion
Currently, there is no solid evidence on the optimal adjuvant 
treatment after metastasectomy of brain metastasis. All three 
treatment options—WBRT, local RT, and observation with best 
supportive care—are used in clinical practice. Thus, this study 
compared the intracranial control rates of these treatments 
after surgical resection of metastatic brain lesions from NSCLC. 
Our results showed that WBRT ± boost after the resection of 
a limited number of brain metastases enhanced intracranial 
control compared to local RT or observation. 
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It is well known that WBRT enhances intracranial control. A 
classic randomized study has shown the advantage of WBRT 
over observation for brain recurrence and neurologic death in 
patients with single brain metastasis, and in the EORTC 22952-
26001 trial, WBRT reduced the 2-year relapse rates at initial 
(59% to 27%) and new (42% to 23%) sites in comparison with 
those of observation after surgical resection of 1 to 3 brain 
metastases [15,16]. Furthermore, a study comparing WBRT 
vs. stereotactic radiosurgery (SRS) alone for resected brain 
metastases reported similar local control rates (83% vs. 74%, p 
= 0.31) but higher 1-year distant brain control for WBRT (70% 
vs. 48%, p = 0.03) [17]. The advantage of WBRT for intracranial 
control may be explained by the ability to control the increased 
probability of seeding during surgery [18,19]. Thus, local RT 
may be insufficient for the control NSR, which may explain our 
findings of no significant difference between the local RT and 
observation groups for IR and NSR.
As for local control, our results showed similar 1-year ISR 
rates between the WBRT ± boost and local RT groups and much 
higher recurrence rates for the observation group, although 
the differences were not significant. Other studies have shown 
similar local control rates. For example, a retrospective study 
of patients who received SRS (median biological effective dose, 
16 Gy10) at the postoperative resection cavity (median volume, 
7.7 cm3) for 1 to 4 brain metastases reported a 1-year control 
rate of 79% [20]. Another phase II study showed similar 
results, with a 1-year local failure of 22% for SRS (median, 18 
Gy) after surgical resection for 1 to 2 brain metastases (median 
size, 2.9 cm) [21]. In addition, a review article reported an 
estimated 1-year actuarial local control of 85% for patients 
who received SRS to the postoperative resection cavity [22]. 
As for overall survival, there were no significant differences 
among the three groups in this study, which was concordant 
with the findings of other studies, in which no difference in 
overall survival was explained by regular follow-up MRI and 
thus timely salvage treatment [15,17]. In addition, since many 
of the patients had a progressive systemic status, the control 
of systemic disease may have affected the overall survival.
Since WBRT does not translate into increased survival, 
there are more reports advocating the use of local RT after 
surgical resection of brain metastases due to the neurotoxicity 
of WBRT. A randomized trial to assess neurocognition in 
patients with brain metastases reported significantly better 
learning and memory function by 4 months for the SRS 
alone group compared to that in the SRS plus WBRT group 
[11]. Thus, a growing number of studies have reported the 
efficacy of omitting WBRT and delivering local RT after 
surgical resection for brain oligometastases [20,21]. However, 
randomized trials that directly compare WBRT with local RT 
after metastasectomy have never been performed. Although 
RTOG 1270 is ongoing, we will have to wait for some years 
to see the results [17,23]. The present study also investigated 
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a lower WBRT dose with a boost to the tumor bed, since 
WBRT neurotoxicity is associated with the total dose and 
fractionation [12,13]. Although no studies have directly 
compared lower WBRT doses to the conventional WBRT 
dose of 30 Gy, the advantage of lower WBRT dose has been 
shown in previous studies on prophylactic cranial irradiation 
(PCI). For example, a French study compared PCI (24 Gy in 8 
fractions, EQD2 26 Gy) vs. no PCI and observed no significant 
difference between the groups in terms of neuropsychological 
function or abnormalities [24]. In another trial performed at 
MD Anderson Cancer Center, 30 patients received PCI (25 Gy in 
10 fractions, EQD2 26.04 Gy) and no significant deterioration 
was observed after PCI [25]. The RTOG 0212 trial compared 
patients who received lower dose PCI (25 Gy in 10 fractions, 
EQD2 26.04 Gy) vs. higher dose PCI (36 Gy in 18 fractions, 
EQD2 36 Gy or twice-daily 24 fractions, EQD2 34.50 Gy), and 
showed significant increase of chronic neurotoxicity in the 
higher dose PCI group [26]. In addition, with advances in 
technology, especially hippocampus-sparing IMRT, WBRT with 
lower neurotoxicity is becoming more feasible [27-29]. Some 
studies have reported that the hippocampus shows radiation 
dose-dependent atrophy and that hippocampus-saving WBRT 
is related with preservation of memory and quality-of-life 
[29,30]. Therefore, if a lower dose of WBRT could control NSR 
and if a boost RT to the tumor bed could ensure local control, 
this treatment method may be best. In this study, WBRT <27 
Gy did not increase NSR in NSCLC patients compared to >27 
Gy; furthermore, an initial site dose ≥42.3 Gy seemed to show 
better initial site control rates.
In addition to postoperative treatment modality, another 
important factor that must be considered for brain metastases 
is targeted therapy, since targeted agents such as erlotinib 
or gefitinib are known to penetrate the blood-brain barrier 
[31,32]. In addition, osimertinib for EGFR T790M-positive 
lung cancer has shown a benefit in progression-free survival 
even in patients with brain metastasis [33]. Thus, as some 
agents are effective in cases of brain metastasis, targeted 
therapy without RT to the brain is gaining interest, not only 
for small asymptomatic brain metastases but also for cases 
of leptomeningeal disease and postoperative brain metastasis 
[34]. In our study, targeted therapy was a significant beneficial 
factor for intracranial recurrence compared to no systemic 
treatment by univariate analysis (p = 0.023) and was a 
borderline beneficial factor by multivariate analysis (p = 0.058), 
whereas chemotherapy was not significant when compared to 
no systemic treatment. However, more patients in the targeted 
therapy group received WBRT (7 of 11) as compared with 
chemotherapy group (12 of 25) and no systemic treatment (7 
of 17) groups. Currently, the role of targeted therapy in the 
management of brain metastasis from lung cancer has not 
been clearly established [34]. The question of whether targeted 
therapy could replace WBRT in the management of brain 
metastasis, including the role of controlling the microscopic 
metastasis such as cerebrospinal fluid contamination from 
surgical resection, remains to be investigated. 
This study has several limitations. Its retrospective nature 
and patient heterogeneity may have biased the results. In 
addition, because of the small number of patients, it was 
difficult to see any significant results in the subgroup analysis 
and reach any clear conclusions. In addition, no common 
objective tool was used to assess neurotoxicity. However, this 
study also has several strengths. First, only postoperative 
brain oligometastases cases with the same primary cancer 
origin were included in this study. This is important since the 
prognosis of brain metastasis varies according to the primary 
cancer type [3]. Second, this study also investigated the unique 
idea of a lower WBRT dose with a boost RT to the tumor bed 
and residual tumor.
In conclusion, WBRT seems to be an essential component 
of adjuvant treatment after resection considering intracranial 
control for brain metastases from NSCLC. In addition, lower 
dose WBRT with a boost to the tumor bed may be an attractive 
option for both increased tumor control and reduced 
neurotoxicity. However, further studies are necessary to 
confirm these findings.
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